为利益关方采取行动,为HTA机构/支付人决策制定更好的现实世界的证据
Ashley A Jaksa1, Alina N Pavel2, Matti Aapro3
1https://ror.org/02efksf92Aetion, Inc., Boston, MA, USA.
为医疗技术评估 (HTA) 决策制定了针对现实世界的证据 (RWE) 生产和分析的最新行动. 这些旨在改善欧盟和加拿大的创新药物的RWE使用.
科学领域:
- 卫生经济学与研究成果研究成果
- 制药政策 制药政策
- 数据科学数据科学数据科学
背景情况:
- 此前,RWE4Decisions倡议概述了在欧盟用于医疗技术评估 (HTA) 的RWE生成和解释的行动.
- 随着决策环境的不断变化和RWE的进步,需要更新欧盟和加拿大的这些行动.
研究的目的:
- 更新利益相关者的行动,以生成,分析和解释现实世界的证据 (RWE).
- 为高度创新的药物提供医疗技术评估 (HTA) 决策的信息.
- 为了应对决策环境和RWE方法的变化.
主要方法:
- 专注小组与各种利益相关者团体进行了讨论,包括HTA机构,行业,临床医生和患者.
- 通过多方利益相关者会议,公开网络研讨会和公众商,共同完善了行动.
- 在利益相关者行动和会议讨论中确定了关键主题.
主要成果:
- 针对每个利益相关者群体,制定了新的,详细的行动.
- 确定的主题包括解决数据碎片化问题,增强RWE方法,并建立RWE使用的共同愿景.
- 强调临床团队在数据收集中的关键作用以及需要科学建议和RWE指导实施.
结论:
- 实施这些行动将促进在HTA中产生RWE的方法论最佳实践.
- 这些更新的行动旨在增强利益相关者对RWE用于高度创新的药物的使用的信任.
更多相关视频
05:47Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
14:43A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
相关概念视频
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Control Governance: Regulatory Bodies and Their Impact
